This information is confidential and intended for accredited investors evaluating Heyday Health. Please verify your identity to proceed.
By accessing this portal, you confirm you are an accredited investor as defined by SEC Rule 501. Information contained herein is confidential and may not be shared without written consent from Heyday, Inc.
Executive overview, financials, market analysis, and corporate documents
Heyday is a men's health platform redefining how men access hormone optimization, weight loss, and longevity care. We combine at-home diagnostics, telehealth consultations, and direct-to-door prescription delivery — all built around personalized treatment plans for men over 35.
Aging men are underserved by traditional healthcare. Most face declining testosterone, weight gain, low energy, and sexual dysfunction. Care is fragmented, inconvenient, or unavailable — and stigma prevents action.
Heyday provides an end-to-end digital experience: arm-based at-home blood testing, clinical consults via telemedicine, and monthly prescription fulfillment. Treatments include TRT, GLP-1s, ED medication, and performance supplements.
Subscription and a la carte pricing. Base subscription of $129/month with average add-ons of $71, totaling $225/month ARPU. Margins of 60%+ via compounding pharmacy partnerships and in-house clinical operations.
The financial model is built on conservative but scalable assumptions across subscriber growth, revenue, margin, and acquisition efficiency.
| Subscribers | MRR | ARR | Gross Profit/Mo | Annual GP |
|---|---|---|---|---|
| 100 | $22,500 | $270,000 | $13,500 | $162,000 |
| 250 | $56,250 | $675,000 | $33,750 | $405,000 |
| 500 | $112,500 | $1,350,000 | $67,500 | $810,000 |
| 1,000 | $225,000 | $2,700,000 | $135,000 | $1,620,000 |
| 2,500 | $562,500 | $6,750,000 | $337,500 | $4,050,000 |
ARPU: $225/month ($129 base + $71 avg add-ons)
$1,800–$2,700+ (8–12 month avg retention)
$150–300 blended (decreasing with organic growth)
6–9x (improving with scale)
60%+ via pharmacy scaling and fulfillment efficiency
Average monthly churn: 8–10% (industry avg 10–15%)
Arm-based collection device (not a fingerprick). No clinic visits or phlebotomist required. Sample collected at home in under 10 minutes and mailed back in a prepaid envelope. Easy, painless, and discreet — designed to reduce friction in diagnostics.
Results reviewed by a licensed provider via secure video or asynchronous chat. Personalized treatment plans created based on lab results and symptom profile. Not a script mill — patients speak to real doctors and get real clinical care.
Medications delivered to the patient's door via partner pharmacies. Monthly auto-refill, reminders, and tracking. Custom compounding and brand options available.
| Product | Category | Pricing |
|---|---|---|
| Testosterone Cypionate 200mg/mL | TRT | $99–139/mo |
| Enclomiphene | TRT Alternative | Add-on |
| Semaglutide (compounded) | GLP-1 Weight Loss | $299+/mo |
| Tirzepatide (compounded) | GLP-1 Weight Loss | $349+/mo |
| Heyday Lab Kit (40+ biomarkers) | Diagnostics | $129/panel |
| Anastrozole | Estrogen Management | Included |
| HCG | Fertility Preservation | Add-on |
The men's health telehealth market sits at the intersection of several macro trends: rising awareness of testosterone deficiency, FDA momentum toward loosening TRT restrictions, the GLP-1 weight loss revolution, and the permanent shift to telehealth delivery.
Direct-response advertising combined with a high-converting quiz funnel, supported by automated follow-ups and a scalable telehealth platform.
Onboarding begins with a short quiz that pre-qualifies leads. Prospects are guided through lab collection, provider consultation, and treatment enrollment with automated reminders at each stage. Current funnel conversion: quiz → enrollment averaging 8-12%.
Heyday positions as a premium men's health brand focused on optimization — not maintenance. We target users frustrated with low-touch care and commoditized prescriptions, offering deeper clinical experience and lifestyle-centric treatment bundles.
| Dimension | Heyday | Hims/Ro | TRT Nation | Gameday |
|---|---|---|---|---|
| Focus | Hormone + metabolic optimization | General men's health | TRT only | In-clinic + telehealth |
| At-Home Labs | ✓ 40+ biomarkers | Varies | ✗ | ✗ (in-clinic) |
| GLP-1 + TRT Combo | ✓ Integrated | Separate products | ✗ | ✓ |
| ARPU | $225 | ~$100 | ~$99 | Varies |
| Monitoring Included | ✓ | Varies | ✗ (extra) | ✓ |
Details available upon request during due diligence. The founding team combines clinical operations experience, digital health product development, and direct-to-consumer growth marketing expertise.
Heyday is building an advisory board with expertise in men's health clinical research, DTC health brand scaling, telehealth regulatory compliance, and pharmacy/compounding operations. Inquiries welcome.
| Metric | Current | Target (12 mo) |
|---|---|---|
| Active Subscribers | Growing | 680 |
| MRR | Growing | $121,720 |
| ARR Run Rate | Growing | $1.46M |
| Gross Margin | 60%+ | 65% |
| Monthly Churn | 8-10% | <8% |
| CAC (Blended) | $150-300 | <$200 |
| LTV:CAC | 6-9x | 10x+ |
Documents available for review by verified accredited investors. Contact contact@heydaymd.com for access.
Heyday, Inc. is a Delaware corporation raising via SAFE (Simple Agreement for Future Equity). Terms, valuation cap, and minimum investment discussed directly with qualified investors. Contact contact@heydaymd.com to schedule a call.